Naprosyn® (Naprometin®, Naprosyn SR®/Naprosyn CR®/Naprosyn LE®/EC-Naprosyn®, Naprosyne®, Naxen® and Proxen®) Naproxen

For the treatment of rheumatoid arthritis, osteoarthritis (degenerative arthritis), ankylosing spondylitis, acute gout, acute musculoskeletal disorders and dysmenorrhoea.

Formulations: Plain-coated 250mg and 500mg tablets • Enteric-coated 375mg tablets • Sustained-release 750mg and 1000mg tablets
Territories: Sweden (SE), Finland (FI)

Patient Information Leaflet(PIL)

Healthcare Professional Information-Summary of the products Characteristics(SmPC)

Please note

Whilst the Patient Information Leaflets (PIL) and Summary of Product Characteristics (SmPC) product information is intended to be helpful, we stress that this is not intended to, and should not, replace the advice of a qualified medical professional.

If you experience any side effects that cause you concern as a result of the use of any of our products and wish to notify us directly please get in touch via our contact page.


Please note that the above links are relevant to the local marketing authorisation requirements only. Patients and carers in Denmark can find similar information at however, if you are from outside Denmark, your local country requirements may differ. Please refer to your local country patient information leaflet(PIL) or summary product characteristic (SPC), if you are a patient or health care professional (HCP) respectively, for further guidance.

Back to all products